Basic information Description References Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Synthetic Anti-infective Drugs >  Antiviral drugs >  Adefovir

Adefovir

Basic information Description References Safety Supplier Related

Adefovir Basic information

Product Name:
Adefovir
Synonyms:
  • treatment Adefovir
  • Tenofovir Desmethyl Impurity
  • 2-(6-amino-9h-purin-
  • Adefovir dipivox (PMEA)
  • [[2-(6-AMino-9H-purin-9-yl)ethoxy] Methyl]phosponic Acid
  • P-[[2-(6-AMino-9H-purin-9-yl)ethoxy]Methyl]phosphonic Acid
  • Adefovir(PMEA)
  • Adefovir98%
CAS:
106941-25-7
MF:
C8H12N5O4P
MW:
273.19
EINECS:
600-789-7
Product Categories:
  • Other Products
  • Aromatics
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • ADEFOVIR DIPIVOXIL
  • (intermediate of adefovir)
  • Intermediate of Adefovir Dipivoxil
  • 106941-25-7
Mol File:
106941-25-7.mol
More
Less

Adefovir Chemical Properties

Melting point:
>260°C
Boiling point:
632.5±65.0 °C(Predicted)
Density 
1.88
storage temp. 
-20°C
solubility 
0.1 M NaOH: ≥5mg/mL
pka
pKa1 2.0, pKa2 6.8(at 25℃)
form 
powder
color 
white to beige
InChI
InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)
InChIKey
SUPKOOSCJHTBAH-UHFFFAOYSA-N
SMILES
P(COCCN1C2C(N=C1)=C(N)N=CN=2)(=O)(O)O
CAS DataBase Reference
106941-25-7(CAS DataBase Reference)
More
Less

Safety Information

Hazard Codes 
T
Risk Statements 
25
Safety Statements 
45
RIDADR 
2811
WGK Germany 
3
RTECS 
SZ6563500
HazardClass 
6.1
PackingGroup 
HS Code 
29339900
Hazardous Substances Data
106941-25-7(Hazardous Substances Data)
More
Less

Adefovir Usage And Synthesis

Description

Adefovir (Trade name: Preveon, Hepsera) is a prescription drug used for the treatment of chronic infections of hepatitis B virus. It can be formulated as the pivoxil prodrug adefovir dipivoxil. However, it shows no effect against HIV-1. As a orally administrated acyclic nucleotide analog reverse transcriptase inhibitor, it blocking the reproduction of HBV through inhibiting the reverse transcriptase in the body. One of its advantages over another anti-HBV drug, lamivudine is that it is much harder for the virus to develop resistance to it.

References

https://www.drugbank.ca/drugs/DB00718
http://en.wikipedia.org/wiki/Adefovir

Chemical Properties

Pale Brown Solid

Uses

Used as an antiviral

Uses

Adefovir has been used to study its anti-retro viral effect on porcine endogenous retrovirus (PERV) activity.

Definition

ChEBI: Adefovir is a member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection. It has a role as a HIV-1 reverse transcriptase inhibitor, a drug metabolite, an antiviral drug, a nephrotoxic agent and a DNA synthesis inhibitor. It is a member of 6-aminopurines, an ether and a member of phosphonic acids. It is functionally related to an adenine. It is a conjugate acid of an adefovir(1-).

Acquired resistance

It has a lower propensity to induce drug resistance than lamivudine. Clinical trials of patients receiving 48 weeks of therapy did not identify any cases of resistance. Longer courses yield resistant strains of HBV with mutations in the DNA polymerase gene; other rare variants of resistant strains have been identified. Lamivudine-resistant strains of HBV retain susceptibility to adefovir.

Pharmaceutical Applications

A nucleotide analog of adenosine monophosphate, administered orally as its prodrug, adefovir dipivoxil.

Biochem/physiol Actions

Adefovir is an antiviral drug that after intracellular conversion to adefovir diphosphate inhibits hepatitis B virus (HBV) DNA polymerase (reverse transcriptase).

Pharmacokinetics

Oral absorption: c. 60%
Cmax 10 mg/kg oral: 18.4 ng/mL
Plasma half-life: c. 7.5 h.
Volume of distribution: 392 mL/kg
Plasma protein binding: Not known
The prodrug is metabolized to adefovir, which is excreted by the kidneys and therefore requires dose adjustment in patients with impaired renal function. It does not induce cytochrome P450 at standard doses and does not influence the metabolism or plasma concentrations of the other licensed medications used in the treatment of hepatitis B.

Clinical Use

Treatment of chronic hepatitis B virus infection in patients >12 years of age

Side effects

It is generally well tolerated, with headache, pharyngitis, abdominal pain and peripheral neuropathy being the most common side effects. Nephrotoxicity has been observed in some patients, with those receiving higher doses and longer courses of therapy at greater risk. Exacerbation of hepatitis has been reported in patients immediately following discontinuation of treatment. Most exacerbations occur within 12 weeks of stopping therapy, and elevations of alanine aminotransferase (ALT) up to 10 times the upper limit of normal can be observed in over 25% of patients. Lactic acidosis has been reported in a few patients and is an indication for immediate discontinuation.

Synthesis

116384-53-3

106941-25-7

The general procedure for the synthesis of ((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid from diethyl ((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphonate is as follows: a 10L three-necked flask was fitted with a mechanical stirrer and thermometer. 1.4 kg (4.26 mol) of diethyl ((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphonate (Intermediate III) and 8 L of acetonitrile were sequentially added to the flask, followed by the addition of trimethylmethylsilyl bromide. The reaction mixture was stirred at room temperature for 1 hour and then heated to reflux for 2 hours. Upon completion of the reaction, the solvent was removed by distillation under reduced pressure. To the residue, 5 L of water was added, the mixture was stirred and the pH was adjusted to 3.2-3.4 with 25% sodium hydroxide solution. the mixture was heated to reflux for 2 hr. Upon completion of the reaction, the reaction mixture was cooled to room temperature and filtered. The filter cake was purified by aqueous recrystallization and dried under vacuum at 70 °C for 8 h. 9-(2-phosphomethoxyethyl)adenine was obtained as a white crystalline solid powder with a yield of 1.07 kg, 86.3% yield and melting point of 298-300 °C.

References

[1] Nucleosides and Nucleotides, 1998, vol. 17, # 8, p. 1445 - 1451
[2] Patent: CN104387421, 2016, B. Location in patent: Paragraph 0032-0034
[3] Patent: CN106317115, 2017, A. Location in patent: Paragraph 0035; 0036; 0039; 0040; 0046; 0047; 0048
[4] Patent: CN106699814, 2017, A. Location in patent: Paragraph 0024-0025
[5] Green Chemistry, 2012, vol. 14, # 8, p. 2282 - 2288

AdefovirSupplier

Cangzhou Weizhidamei Pharmaceutical Co., Ltd. Gold
Tel
13426038769
Email
askmryu@163.com
Huangshi Jingchi?Medicine?Co.,?Ltd Gold
Tel
17771967576; 17771967576
Email
234107690@qq.com
Shanghai Boyle Chemical Co., Ltd.
Tel
021-50182298 021-50180596
Email
sales@boylechem.com
J & K SCIENTIFIC LTD.
Tel
18210857532; 18210857532
Email
jkinfo@jkchemical.com
future industrial shanghai co., ltd
Tel
400-0066400 13621662912
Email
sales@jonln.com